Published in J Exp Med on September 01, 1981
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest (1985) 2.32
Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest (2008) 1.94
Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect Immun (1991) 1.90
Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect Immun (1986) 1.88
Serum bicarbonate levels and the progression of kidney disease: a cohort study. Am J Kidney Dis (2009) 1.84
Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med (1983) 1.83
Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood (2015) 1.58
Structural transitions of complement component C3 and its activation products. Proc Natl Acad Sci U S A (2006) 1.57
Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet (2010) 1.57
Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect Immun (1993) 1.56
Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol (2015) 1.52
Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem J (1994) 1.42
Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury. J Clin Invest (2010) 1.42
Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans. Infect Immun (1992) 1.41
Complement in age-related macular degeneration: a focus on function. Eye (Lond) (2011) 1.39
Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c. Proc Natl Acad Sci U S A (1982) 1.33
Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol (1988) 1.32
The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J (1986) 1.26
Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med (1996) 1.23
Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem (2009) 1.21
Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem (2010) 1.20
Human peripheral blood monocyte-derived macrophages produce haemolytically active C3 in vitro. Immunology (1983) 1.16
Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B. Proc Natl Acad Sci U S A (1986) 1.14
The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol (2007) 1.14
Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J (2015) 1.12
Complement activation in the injured central nervous system: another dual-edged sword? J Neuroinflammation (2012) 1.11
The role of complement in tumor growth. Adv Exp Med Biol (2014) 1.11
Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement. J Biol Chem (2009) 1.09
Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury. J Clin Invest (1987) 1.08
Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology (2008) 1.06
Membrane protein Crry maintains homeostasis of the complement system. J Immunol (2008) 1.04
The complotype: dictating risk for inflammation and infection. Trends Immunol (2012) 1.03
Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum (2008) 1.02
Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J (2011) 1.01
Polyanion-induced self-association of complement factor H. J Immunol (2009) 1.01
Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. MBio (2011) 0.99
Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products. Biochem J (1988) 0.98
Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro. Clin Exp Immunol (2009) 0.97
The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol (2010) 0.95
The role of the complement system in metabolic organs and metabolic diseases. Semin Immunol (2013) 0.95
Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement. Front Immunol (2013) 0.94
The pathogenesis of hyaline arteriolosclerosis. Am J Pathol (1986) 0.90
Antibody-dependent alternate pathway of complement activation in opsonophagocytosis of Porphyromonas gingivalis. Infect Immun (1991) 0.90
Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going. Transl Med UniSa (2014) 0.90
Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol (2013) 0.87
Role of complement in protection against Cryptococcus gattii infection. Infect Immun (2008) 0.87
Leishmanial protein kinases phosphorylate components of the complement system. EMBO J (1991) 0.87
The role of properdin in zymosan- and Escherichia coli-induced complement activation. J Immunol (2012) 0.87
The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2010) 0.87
Structure of Complement C3(H2O) Revealed By Quantitative Cross-Linking/Mass Spectrometry And Modeling. Mol Cell Proteomics (2016) 0.86
Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin Exp Immunol (1993) 0.86
Solution structure of CCP modules 10-12 illuminates functional architecture of the complement regulator, factor H. J Mol Biol (2012) 0.86
Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement. Mol Immunol (2011) 0.86
Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement. Biochem J (1988) 0.85
Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression. Biochem J (1992) 0.83
A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors. J Immunol (2014) 0.83
The role of the complement system in acute kidney injury. Semin Nephrol (2013) 0.83
Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum. J Clin Invest (1984) 0.83
Complementary recognition of alternative pathway activators by decay-accelerating factor and factor H. Infect Immun (1998) 0.83
Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway. Front Immunol (2016) 0.82
Acute local inflammation alters synthesis, distribution, and catabolism of third component of complement (C3) in rabbits. J Clin Invest (1984) 0.82
Spatiotemporal dynamics of complement C5a production within bacterial extracellular polymeric substance. J Innate Immun (2013) 0.81
Formation of C3-IgG complexes in serum by aggregated IgG and by non-immunoglobulin activators of complement. Immunology (1987) 0.81
Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factor. Clin Exp Immunol (1990) 0.81
Non-enzymic activation of the covalent binding reaction of the complement protein C3. Biochem J (1983) 0.81
Functional characterization of a ficolin-mediated complement pathway in amphioxus. J Biol Chem (2011) 0.80
Solution Structures of Complement C2 and Its C4 Complexes Propose Pathway-specific Mechanisms for Control and Activation of the Complement Proconvertases. J Biol Chem (2016) 0.79
Protection of host cells by complement regulators. Immunol Rev (2016) 0.79
Point mutations in the paramyxovirus F protein that enhance fusion activity shift the mechanism of complement-mediated virus neutralization. J Virol (2013) 0.79
Activation of the complement system. Agents Actions (1983) 0.79
Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense. Immunol Rev (2016) 0.78
Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies. J Immunol (2013) 0.78
Ovariectomy and subsequent treatment with estrogen receptor agonists tune the innate immune system of the hippocampus in middle-aged female rats. PLoS One (2014) 0.78
Acute phase proteins are major clients for the chaperone action of α₂-macroglobulin in human plasma. Cell Stress Chaperones (2012) 0.78
AMD and the alternative complement pathway: genetics and functional implications. Hum Genomics (2016) 0.78
Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. Biomaterials (2014) 0.77
The neutralizing capacity of antibodies elicited by parainfluenza virus infection of African Green Monkeys is dependent on complement. Virology (2014) 0.76
Post-bone marrow transplant thrombotic microangiopathy. Bone Marrow Transplant (2016) 0.76
A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. J Am Soc Nephrol (2015) 0.76
Mutations in Complement Factor H Impair Alternative Pathway Regulation on Mouse Glomerular Endothelial Cells in Vitro. J Biol Chem (2016) 0.76
Activation of complement system in kidney after ketoprofen-induced kidney injury in sheep. Acta Vet Scand (2015) 0.75
Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity. Front Microbiol (2017) 0.75
Evolution of the complement system: from defense of the single cell to guardian of the intravascular space. Immunol Rev (2016) 0.75
Quantitative Modeling of the Alternative Pathway of the Complement System. PLoS One (2016) 0.75
Complement Factor H Binds to Human Serum Apolipoprotein E and Mediates Complement Regulation on High Density Lipoprotein Particles. J Biol Chem (2015) 0.75
Preoperative Low Serum Bicarbonate Levels Predict Acute Kidney Injury After Cardiac Surgery. Medicine (Baltimore) (2016) 0.75
A Novel Complotype Combination Associates with Age-Related Macular Degeneration and High Complement Activation Levels in vivo. Sci Rep (2016) 0.75
A C3(H20) recycling pathway is a component of the intracellular complement system. J Clin Invest (2017) 0.75
Complement Protein C3 Suppresses Axon Growth and Promotes Neuron Loss. Sci Rep (2017) 0.75
Complement in Kidney Transplantation. Front Med (Lausanne) (2017) 0.75
Tissue sulfhydryl groups. Arch Biochem Biophys (1959) 61.89
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry (1976) 7.80
Isolation and characterization of two beta1-glycoproteins of human serum. J Exp Med (1960) 7.25
Isolation and description of proteins related to the human complement system. Acta Soc Med Ups (1961) 3.98
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology (1973) 3.41
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med (1975) 3.12
Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci U S A (1980) 3.00
Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement. J Immunol (1966) 2.98
Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med (1980) 2.94
The covalent-binding reaction of complement component C3. Biochem J (1981) 2.80
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Human anaphylatoxin (C3a) from the third component of complement. Primary structure. J Biol Chem (1975) 2.08
Characterization of alkylamine-sensitive site in alpha 2-macroglobulin. Proc Natl Acad Sci U S A (1979) 2.05
Initiation of C3 cleavage in the alternative complement pathway. J Immunol (1975) 1.94
Mechanism of action of factor D of the alternative complement pathway. J Exp Med (1978) 1.87
Covalent binding and hemolytic activity of complement proteins. Proc Natl Acad Sci U S A (1980) 1.77
Third component of human complement: appearance of a sulfhydryl group following chemical or enzymatic inactivation. Biochemistry (1980) 1.67
Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry (1981) 1.58
Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin. J Immunol (1977) 1.47
Third component of human complement: structural requirements for its function. Biochemistry (1980) 1.38
Treatment of human complement components C4 and C3 with amines or chaotropic ions. Evidence of a functional and structural change that provides uncleaved C4 and C3 with properties of their soluble activated froms, C4b and C3b. Scand J Immunol (1981) 1.22
Effect of methylamine on the structure and function of the fourth component of human complement, C4. J Biol Chem (1980) 1.20
The separation of functionally distinct forms of the third component of human complement (C3). Biochem J (1981) 0.99
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (1990) 14.46
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49
Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science (1988) 7.96
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G. Science (1968) 7.70
Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med (1969) 7.43
Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A (1985) 7.15
The C3-activator system: an alternate pathway of complement activation. J Exp Med (1971) 7.07
C3 proactivator convertase and its mode of action. J Exp Med (1972) 6.94
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J Exp Med (1967) 6.72
Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol (1970) 6.58
Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med (1982) 6.56
Complement. Annu Rev Biochem (1975) 6.00
The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol (1993) 5.88
The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med (1968) 5.78
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol (1989) 5.39
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
Chemistry and reaction mechanisms of complement. Adv Immunol (1968) 5.02
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A (1978) 4.94
The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol (1997) 4.76
Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice. J Immunol (1989) 4.70
Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. J Immunol (1985) 4.44
Regulation of gamma interferon production by natural killer cells in scid mice: roles of tumor necrosis factor and bacterial stimuli. Infect Immun (1991) 4.18
Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med (1984) 4.00
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation. Cell (1985) 3.81
The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase. J Exp Med (1968) 3.71
Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A (1996) 3.62
Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest (1970) 3.55
A T cell-independent mechanism of macrophage activation by interferon-gamma. J Immunol (1987) 3.55
Complement. Annu Rev Biochem (1969) 3.51
Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse. Immunol Rev (1991) 3.49
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol (1980) 3.41
Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med (1995) 3.37
Molecular analysis of the membrane attack mechanism of complement. J Exp Med (1972) 3.35
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A (1994) 3.34
Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature (1994) 3.34
Deficiency of the fifth component of complement in mice with an inherited complement defect. J Exp Med (1967) 3.28
Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol (1971) 3.25
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell (1998) 3.25
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum. J Exp Med (1975) 3.21
Lysis of erythrocytes by complement in the absence of antibody. J Exp Med (1970) 3.19
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med (1975) 3.12
A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet (1999) 3.12
Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science (2001) 3.11
Gamma interferon limits access of Listeria monocytogenes to the macrophage cytoplasm. J Exp Med (1989) 3.08
In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect Immun (1992) 3.07
Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med (1993) 3.06
A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med (1998) 3.03
Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement. J Immunol (1966) 2.98
The ninth component of human complement: isolation, description and mode of action. Immunology (1969) 2.96
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med (1980) 2.94
Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med (1974) 2.93
Studies on the mode of action of the fifth, sixth and seventh component of human complement in immune haemolysis. Immunology (1967) 2.93
Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med (1972) 2.91
Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J (1994) 2.82
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A (1990) 2.79
The role of properdin in the alternate pathway of complement activation. J Exp Med (1974) 2.77
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Release of nitric oxide during the T cell-independent pathway of macrophage activation. Its role in resistance to Listeria monocytogenes. J Immunol (1993) 2.73
Deficiency of the sixth component of complement in rabbits with an inherited complement defect. J Exp Med (1966) 2.73
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 2.68
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med (1976) 2.66
The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med (1973) 2.64
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. J Immunol (1983) 2.61
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A (1999) 2.60
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
The membrane attack complex of complement. Annu Rev Immunol (1986) 2.57
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci U S A (2001) 2.56
Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science (2001) 2.52
Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J Exp Med (1973) 2.50
The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution. J Exp Med (1973) 2.44
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A (1986) 2.39
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med (1979) 2.39
Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature (1982) 2.35
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33